A Phase 3 interventional study of Vorinostat and bortezomib in Multiple Myeloma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing vorinostat in Multiple Myeloma — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Multiple Myeloma.
Among the 19 studies testing vorinostat in Multiple Myeloma, this one has the largest enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2008, is the only one in phase 3, and was the 9th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →None of the 19 studies testing vorinostat in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 8 · Phase 3 1
First in 2000; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 637 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 31 across the 17 interventional studies. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
20 studies in Multiple Myeloma by Merck & Co., Inc: none open now, 1 under way, none of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 20 studies in Multiple Myeloma by Merck & Co., Inc, this one has the largest enrollment, is one of 3 that started in 2008, is one of 4 in phase 3, and was the 8th registered.
Merck & Co., Inc’s Multiple Myeloma studies by the year they started, since 2000.
1 of the studies testing vorinostat in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01297764Hackensack Meridian HealthA Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing vorinostat in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 20 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study of the efficacy and safety of bortezomib administered in combination with vorinostat in patients with relapsed or refractory multiple myeloma. Histone deacetylases (HDAC) facilitate gene transcription by modulating the uncoiling of chromatin. HDAC function is dysregulated in hematologic and solid malignancies, and this dysregulation may result in over-expression of oncogenes. Thus, inhibition of HDACs may result in anti-cancer effects. HDAC inhibitors, like vorinostat, represent a new class of antitumor agents that have the ability to induce antiproliferative effects including cyto-differentiation, cell cycle growth arrest or apoptosis in various cancer cell lines. Several studies have investigated the in vitro antimyeloma activity of vorinostat in combination with bortezomib and have demonstrated that vorinostat may act synergistically with bortezomib to modulate tumor cell growth. Mitsiades et al have shown that vorinostat enhances the sensitivity of bortezomib. Pei et al found that exposure of human multiple myeloma cell lines \& patient-derived multiple myeloma cells to bortezomib and vorinostat resulted in synergistic interactions as a result of: (1) Interruption of NF-kB \& related signaling pathways (JNK, XIAP, Mcl-1, etc.) (2) Inhibition of Hsp90 (3)Induction of ER stress signal and (4) acetylation of Dynein/disruption of aggresome function/formation, salvage for ubiquitinated proteins. In addition a marked increase in mitochondrial injury, caspase activation, and apoptosis was also observed. Bortezomib is indicated for the treatment of patients with multiple myeloma. Two Phase I dose-ranging studies of a regimen combining vorinostat and bortezomib among patients with relapsed as well asend-stage, refractory multiple myeloma have been conducted. These studies enrolled a total of 57 patients. In these studies, administration of vorinostat with standard doses of bortezomib resulted in responses in 20/45 (44%) evaluable patients (Weber et al 2007, Badros et al 2007). The purpose of the present study is to definitively evaluate the clinical activity of vorinostat in combination with bortezomib inpatients with multiple myeloma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
Drug: Vorinostat · Drug: bortezomib
Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
Drug: bortezomib · Drug: placebo to vorinostat
Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
Also known as: Zolinza
1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
Also known as: Velcade
Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
Progression-Free Survival (PFS)
Progression-free survival was measured from the start of the treatment to the time when the criteria for progression was met or death due to any cause (whichever is first recorded). Response to study therapy was assessed using European Blood and Marrow Transplantation Group (EBMT) Criteria. A stratified Cox proportional hazards model was used with Efron's likelihood approximation to account for ties in event times.
Time frame: From randomization to event of disease progression or death assessed up to 32 months (final study analysis)
Number of Participants With Grade 3-5 Clinical or Laboratory Adverse Events (AEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product/protocol-specified procedure, whether or not considered related to the medicinal product/protocol-specified procedure. Any worsening of a preexisting condition temporally associated with the use of the product was also an AE. Grades come from the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Per protocol, clinical and laboratory AEs are presented as a combined total for each grade.
Time frame: Up to 722 days
Overall Survival
Overall survival was measured from the start of the treatment to death due to any cause. Overall Survival is represented as the number of deaths per 100-person- months and was computed by dividing the number of participants with an event of death that occurred during the study follow-up period by the total duration of follow-up (in 100 months) for all the participants in each cohort since participants had different lengths of follow-up.
Time frame: From randomization up to 32 months (final study analysis)
Time to Progression
Time to progression was measured from the start of the treatment to the time when the criteria for progression was met or death due to myeloma (whichever is first recorded). Response to study therapy was assessed using European Blood and Marrow Transplantation Group (EBMT) Criteria. A stratified Cox proportional hazards model was used with Efron's likelihood approximation to account for ties in event times.
Time frame: Baseline and at the end of each 21-day Cycle assessed up to 32 months (final study analysis)
Objective Response Rate
Objective response rate was measured as the proportion of patients who achieved a confirmed partial response or better during the course of the study. Response to study therapy was assessed using EBMT Criteria and confirmed by Independent Adjudication Review.
Time frame: Baseline and at the end of each 21-day Cycle assessed up to 32 months (final study analysis)
This study enrolled participants with an established diagnosis of multiple myeloma based on standard criteria that have received at least 1 but not more than 3 prior anti-myeloma regimens and have demonstrated progressive disease after the most recent treatment regimen. Additional inclusion and exclusion criteria applied.
| Milestone | Vorinostat + Bortezomib | Placebo + Bortezomib |
|---|---|---|
| Started | 317 | 320 |
| Treated | 315 | 320 |
| Completed | 20 | 24 |
| Not completed | 297 | 296 |
| Withdrew: Lack of efficacy | 112 | 144 |
| Withdrew: Physician decision | 26 | 18 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Withdrawal by subject | 89 | 61 |
| Withdrew: Adverse event | 61 | 62 |
| Withdrew: Death | 5 | 8 |
| Withdrew: Not treated | 2 | 0 |
Progression-free survival was measured from the start of the treatment to the time when the criteria for progression was met or death due to any cause (whichever is first recorded). Response to study therapy was assessed using European Blood and Marrow Transplantation Group (EBMT) Criteria. A stratified Cox proportional hazards model was used with Efron's likelihood approximation to account for ties in event times.
| Months | Vorinostat + Bortezomib | Placebo + Bortezomib |
|---|---|---|
| Progression-Free Survival (PFS) | 7.63 ± 6.87 | 6.83 ± 5.67 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product/protocol-specified procedure, whether or not considered related to the medicinal product/protocol-specified procedure. Any worsening of a preexisting condition temporally associated with the use of the product was also an AE. Grades come from the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Per protocol, clinical and laboratory AEs are presented as a combined total for each grade.
| Participants | Vorinostat + Bortezomib | Placebo + Bortezomib |
|---|---|---|
| Grade 3 | 272 | 240 |
| Grade 4 | 108 | 85 |
| Grade 5 | 11 | 17 |
Overall survival was measured from the start of the treatment to death due to any cause. Overall Survival is represented as the number of deaths per 100-person- months and was computed by dividing the number of participants with an event of death that occurred during the study follow-up period by the total duration of follow-up (in 100 months) for all the participants in each cohort since participants had different lengths of follow-up.
| Events/100-person Months | Vorinostat + Bortezomib | Placebo + Bortezomib |
|---|---|---|
| Overall Survival | 1.7 ± 1.56 | 1.9 ± 1.75 |
Time to progression was measured from the start of the treatment to the time when the criteria for progression was met or death due to myeloma (whichever is first recorded). Response to study therapy was assessed using European Blood and Marrow Transplantation Group (EBMT) Criteria. A stratified Cox proportional hazards model was used with Efron's likelihood approximation to account for ties in event times.
| Months | Vorinostat + Bortezomib | Placebo + Bortezomib |
|---|---|---|
| Time to Progression | 7.73 ± 7.00 | 7.03 ± 6.33 |
Objective response rate was measured as the proportion of patients who achieved a confirmed partial response or better during the course of the study. Response to study therapy was assessed using EBMT Criteria and confirmed by Independent Adjudication Review.
| Percentage of Participants | Vorinostat + Bortezomib | Placebo + Bortezomib |
|---|---|---|
| Objective Response Rate | 56.2 ± 50.5 | 40.6 ± 35.2 |
Collected over Up to 722 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vorinostat + Bortezomib | — | 130/315 (41.3%) | 312/315 (99%) |
| Placebo + Bortezomib | — | 138/320 (43.1%) | 306/320 (95.6%) |
| Event | Vorinostat + Bortezomib | Placebo + Bortezomib |
|---|---|---|
| Accidental overdoseInjury, poisoning and procedural complications | 32/315 | 27/320 |
| PneumoniaInfections and infestations | 14/315 | 13/320 |
| Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/315 | 13/320 |
| DiarrhoeaGastrointestinal disorders | 9/315 | 10/320 |
| ThrombocytopeniaBlood and lymphatic system disorders | 9/315 | 3/320 |
| PyrexiaGeneral disorders | 6/315 | 9/320 |
| VomitingGastrointestinal disorders | 8/315 | 7/320 |
| GastroenteritisInfections and infestations | 6/315 | 0/320 |
| Herpes zosterInfections and infestations | 0/315 | 6/320 |
| FatigueGeneral disorders | 3/315 | 5/320 |
| Event | Vorinostat + Bortezomib | Placebo + Bortezomib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 194/315 | 133/320 |
| NauseaGastrointestinal disorders | 193/315 | 126/320 |
| ThrombocytopeniaBlood and lymphatic system disorders | 172/315 | 106/320 |
| VomitingGastrointestinal disorders | 140/315 | 80/320 |
| FatigueGeneral disorders | 125/315 | 96/320 |
| NeutropeniaBlood and lymphatic system disorders | 112/315 | 95/320 |
| AnaemiaBlood and lymphatic system disorders | 91/315 | 79/320 |
| ConstipationGastrointestinal disorders | 64/315 | 86/320 |
| NeuralgiaNervous system disorders | 82/315 | 86/320 |
| Decreased appetiteMetabolism and nutrition disorders | 75/315 | 85/320 |
| Age, Continuous(Years) | Vorinostat + Bortezomib | Placebo + Bortezomib | Total |
|---|---|---|---|
| Mean | 60.9 ± 10.0 | 62.7 ± 10.0 | 61.8 ± 10.0 |
| Age, Customized(Participants) | Vorinostat + Bortezomib | Placebo + Bortezomib | Total |
|---|---|---|---|
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 200 | 181 | 381 |
| From 65-84 years | 116 | 137 | 253 |
| 85 years and over | 1 | 2 | 3 |
| Sex: Female, Male(Participants) | Vorinostat + Bortezomib | Placebo + Bortezomib | Total |
|---|---|---|---|
| Female | 126 | 134 | 260 |
| Male | 191 | 186 | 377 |
| Ethnicity (NIH/OMB)(Participants) | Vorinostat + Bortezomib | Placebo + Bortezomib | Total |
|---|---|---|---|
| Hispanic or Latino | 32 | 23 | 55 |
| Not Hispanic or Latino | 285 | 297 | 582 |
| Unknown or Not Reported | 0 | 0 | 0 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2008 to primary completion in Sep 2011, 33 months.
Results were first posted in Apr 2021, 9 years 7 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 33 months is below that.
Counting every sponsor, half of 180 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat